Why Nigeria Was Disqualified From Global Vaccine Bid By WHO

The World Health Organisation-led COVAX global initiative has reportedly disqualified Nigeria for the Pfizer vaccines following the country’s poor facilities and inability to meet the standard requirement of being able to store the vaccines at the required -70 degrees Celsius.

The Federal Government had stated that it was expected to receive 100,000 doses through the COVAX initiative, which was established to ensure quick and equitable access to COVID-19 vaccines for all countries, regardless of income level.

Speaking at a virtual press conference, The Director WHO for African Region, Dr Matshidiso Moeti, said only four African countries were shortlisted for the Pfizer vaccine out of the 13 that applied.

OnyxNews Nigeria gathered in a report by The PUNCH, Moeti said WHO could not risk the Pfizer vaccines being wasted.

She said, “Around 320,000 doses of the Pfizer-BioNTech vaccine have been allocated to four African countries – Cape Verde, Rwanda, South Africa and Tunisia. This vaccine has received WHO Emergency Use Listing but requires countries to be able to store and distribute doses at minus 70 degrees Celsius.

“To access an initial limited volume of Pfizer vaccine, countries were invited to submit proposals.

Why Nigeria Was Disqualified From Global Vaccine Bid By WHO

“Thirteen African countries submitted proposals and were evaluated by a multi-agency committee based on current mortality rates, new cases and trends, and the capacity to handle the ultra-cold chain needs of the vaccine.

“This announcement allows countries to fine-tune their planning for COVID-19 immunisation campaigns.

READ World’s Richest Football Clubs in 2021, See Top 20 List

“We urge African nations to ramp up readiness and finalise their national vaccine deployment plans. Regulatory processes, cold chain systems and distribution plans need to be in place to ensure vaccines are safely expedited from ports of entry to delivery. We can’t afford to waste a single dose.”

The Director-General of the Nigerian Institute of Medical Research, Prof Babatunde Salako, had told the publication that there is no enough space at the moment to store the Pfizer vaccines at that temperature. But the Executive Director of the National Primary Health Care Development Agency, Dr Faisal Shuaib, had described the report as fake, saying Nigeria had the capacity to store the vaccines and had taken journalists on a tour of its facility in Abuja.

Only South Africa, Morocco, Tunisia, Egypt and Ethiopia have higher infection rates than Nigeria. But Morocco and Egypt have already independently obtained vaccines and begun distribution while South Africa, which has the highest burden of the disease in Africa, has already procured one million doses of the Oxford-AstraZeneca vaccine, produced in India but has yet to begin distribution.

Nigeria has, however, received no COVID-19 vaccine even as its rate of infection has continued to increase. Unlike the other vaccines on the market, the BioNTech/Pfizer vaccine, which has the highest WHO rating, is expected to be stored at 70 degrees Celsius which Nigeria could not meet.

However, the WHO regional director said countries that failed to make the Pfizer list could get the Oxford-AstraZeneca vaccine later in the month although it has not yet been endorsed by the health organisation. It was gathered that the Oxford-AstraZeneca vaccine does not need to be stored in a cold environment.